Loading stock data…
XGN
$3.98+1.03 (+34.92%)
After Hours$3.92-0.06 (-1.51%)· Last close May 11
Exagen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Exagen Inc. in the Healthcare sector is trading at $3.98. The stock is currently near its 52-week low of $2.59, remaining 41.0% below its 200-day moving average. Technical signals show overbought RSI of 79 and bullish MACD crossover, explaining why XGN maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 79) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.98
Potential Upside
5%
Whystock Fair Value$4.18
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$64.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-97.31%
Volume
Today's trading volume
6.18M
Recent News
Exagen Q1 Earnings Call Highlights
Exagen (NASDAQ:XGN) reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter. The autoimmune diagnostics
Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Losses
Exagen delivered record first-quarter revenue and improved adjusted EBITDA metrics as the autoimmune diagnostics company continued expanding adoption of its AVISE CTD testing platform. Key Investor TakeawaysExagen Inc.
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
Exagen (XGN) delivered earnings and revenue surprises of +29.17% and +4.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Reports Break-Even Earnings for Q1
AtriCure (ATRC) delivered earnings and revenue surprises of +100.00% and +1.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Does Exagen (XGN)’s 200%+ Upside Potential Make It One of the Best Penny Stocks Set to Explode?
Exagen Inc. (NASDAQ:XGN) earns a spot on our list of the best penny stocks set to explode. As of April 8, 2026, analyst sentiment toward Exagen Inc. (NASDAQ:XGN) remains bullish, with over 80% of covering analysts maintaining ‘Buy’ ratings on the stock. The consensus price target of $10 implies a 235.01% upside. On March 11, […]